Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21156825 | 0.93 | DYRK1A (0.61) | DYRK1AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL30593441 | 0.93 | DYRK1A (0.61) | DYRK1AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL21156829 | 0.90 | DYRK1A (0.59) | DYRK1AMAPTSMN1; SMN2TP53 | |
| SCHEMBL21156271 | 0.83 | DYRK1A (0.58) | DYRK1AMAPTGAA | |
| SCHEMBL30593440 | 0.83 | DYRK1A (0.59) | DYRK1ASMN1; SMN2TP53 | |
| SCHEMBL21156830 | 0.83 | DYRK1A (0.59) | DYRK1ASMN1; SMN2TP53 | |
| SCHEMBL30593442 | 0.78 | DYRK1A (0.59) | DYRK1AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL21156828 | 0.78 | DYRK1A (0.59) | DYRK1AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL22191346 | 0.77 | DYRK1A (0.48) | DYRK1AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL21156833 | 0.77 | DYRK1A (0.56) | DYRK1AMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630803-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-05-30 | — | — | US | disclosed |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3717475-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-10 | — | — | US | disclosed |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210032601-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-04 | — | — | US | disclosed |
| US-20210032601-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-04 | — | — | US | disclosed |
| CN-111936490-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2020-11-13 | — | — | CN | disclosed |
| US-20200306257-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2020-10-01 | — | — | US | disclosed |
| US-20200306257-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2020-10-01 | — | — | US | disclosed |
| WO-2019136320-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306257-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | DYRK1A 464/4885MEN1 1054/4885KMT2A 1577/4885 |
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | IAPP, DYRK1A, GLP1R | DYRK1A 2/4885MEN1 1782/4885KMT2A 2161/4885 |
| US-12630803-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | GLP1R, DYRK1A, DYRK1B | DYRK1A 2/4885MEN1 1570/4885KMT2A 2453/4885 |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | MAP3K20, MAP3K1, PACSIN2 | DYRK1A 464/4885MEN1 1054/4885KMT2A 1577/4885 |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | IAPP, GLP1R, GPR119 | DYRK1A 5/4885MEN1 1727/4885KMT2A 3042/4885 |
| US-20210032601-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | IAPP, GLP1R, GPR119 | DYRK1A 5/4885MEN1 1727/4885KMT2A 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.